.png){kind=icon}
返回
Advancing cell-based cancer immunotherapy through stem cell engineering
.png){kind=icon}
OA
AI
DOI：10.1016/j.stem.2023.02.009.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the treatment of hemato- logical malignancies. Although an important step forward for the field, autologous CAR-T therapies are hindered by high costs, manufacturing challenges, and limited efficacy against solid tumors. With ongoing progress in gene editing and culture techniques, engineered stem cells and their application in cell therapy are poised to address some of these challenges. Here, we review stem cell-based immunotherapy ap- proaches, stem cell sources, gene engineering and manufacturing strategies, therapeutic platforms, and clin- ical trials, as well as challenges and future directions for the field.
Keyword:
NATURAL-KILLER-CELLS
CAR-T-CELLS
VERSUS-HOST-DISEASE
ACUTE LYMPHOBLASTIC-LEUKEMIA
HUMAN HEMATOPOIETIC STEM
ADULT B-CELL
NK CELLS
ANTITUMOR-ACTIVITY
PROGENITOR CELLS
CLINICAL-TRIAL
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
20.4
论文数:
3.6K
被引数:
3.1W
机构
引用论文
分享收藏分享收藏Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf下一代嵌合抗原受体T细胞疗法: 下架.png)
BIODRUGS
OAAI
BIODRUGSIF6.9
OAAI分享收藏Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells造血干细胞基因工程产生不变的自然杀伤T细胞OAAI
OAAI分享收藏
查看更多内容